Large Western U.S. Health System Studies Remdesivir & Finds It Lowers Mortality by 40% in COVID-19 Patients While on Low Flow Oxygen

While the World Health Organization (WHO) Solidarity trial concluded that Gilead’s Remdesivir was not effective in treating COVID-19, that didn’t stop the use in the United States and many other market as a pivotal trial sponsored by the National Institutes of Health (NIH) indicated some efficacy, although the endpoints to that study were modified toward the end of the study.  Now one of the largest health systems in America, Providence, reports on published study results evidencing the antiviral drug is actually associated with lower mortality as compared to best supportive care. Specifically the large health system found that the drug from Gilead lowers mortality by 40% in COVID-19 patients who receive treatment while on low flow oxygen. The retrospective study included a number of limitations including no assessment of adverse events.

Note that this particular retrospective study was conducted back between Feb. 28, 2020 and May 28, 2020, before Remdesivir was a standard of care and based on the prospective enrollment criteria used by the Gilead-sponsored SIMPLE-Severe randomized controlled trial.     The National Institute of Health sponsored ACTT-1 ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee